Definitive Contract HHSN272201600033C
Award Date 8/24/16
Potential Completion Date 8/25/17
Potential Value $221K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Oxnard, CA 93033, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase II contract to Luna Innovations Incorporated, a manufacturer of goods, for the development of "Innovative Oral Formulations for Anti-TB Drugs". The firm-fixed-price contract, with a potential value of $1,499,796.00, was awarded on August 28, 2018, and is set to be completed by November 30, 2020. As a...
- The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Phase I contract to Aquarius Biotechnologies Inc. for the development of CAPREOMYCIN COCHLEATES: ORAL FORMULATIONS FOR TUBERCULOSIS. The firm-fixed-price contract, valued at $224,735.00, has a period of performance through March 16, 2016. This SBIR contract supports early-stage research and development of an oral formulation of...
- Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
- This is a SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a firm fixed price of $300,000.00 and is for the development of a point-of-care test to measure antibiotic concentrations in the blood for tuberculosis (TB) treatment. Nanocomposix has prior experience providing products...
- This is a $249,490.00 Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Strategic Drug Solutions, Inc., a small, minority-owned, and Asian-Pacific American-owned business. The contract is for the SBIR Program Phase I research and development of "Efficacy of Oral Aminoglycoside-Cochleate Formulations," with a place of performance in Chino Hills, California. The contract was...
- <p>The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Aldatu Biosciences, Inc. for the development of a rapid, sensitive, and cost-effective method to detect drug-resistant HIV minority variants. The contract, valued at $298,690.00, is a Definitive Contract with a Firm Fixed Price pricing type. The contract has an ultimate completion date of December 14, 2017.</p>
- This federal contract award, with ID HHSN272201000037C, was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Coordinated Program Development LLC, a small business. The contract, valued at $248,901.00, is for the development of oral aminoglycoside-cochleate formulations, as part of the Small Business Innovation Research (SBIR) program Phase I. The contract is a definitive, firm-fixed-price contract with a completion date of September 14, 2011.
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $449,984 firm fixed-price contract to Applied Biotechnology Institute Inc., a veteran-owned small business, to develop a mucosal prophylactic vaccine against coccidioidomycosis. The contract, with a completion date of August 30, 2018, is a direct result of NIAID's research efforts in the area of allergy and infectious diseases. Applied Biotechnology Institute Inc. has previously received federal grants from NIAID and the...